• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

    2/27/24 9:00:00 AM ET
    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $BMRN alert in real time by email

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive.

    "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and biotech companies and David's broad pharmaceutical industry knowledge and extensive experience in operations and quality functions will add valuable perspectives as we continue to focus on growing NorthStar and meeting the needs of patients who need better treatment options. Many important strategic decisions need to be made to drive our growth, and Barbara and David will provide well-informed counsel for those critical decisions."

    Ms. Bodem is an active board director and former public company Chief Financial Officer with extensive global experience in branded and generic pharmaceuticals, medical device and healthcare technology and services. She is currently a Board Director for Enovis Corporation (NYSE:ENOV), Option Care Health (NASDAQ:OPCH) and BioMarin Pharmaceutical (NASDAQ:BMRN). Previously, Ms. Bodem has served as a director for Syneos Health (NASDAQ:SYNH), Turning Point Therapeutics (NASDAQ:TPTX) and Invacare Corporation (OTC:IVCRQ, NYSE:IVC). She also served in finance roles of increasing responsibility at Eli Lilly, Hospira, Mallinckrodt Pharmaceuticals and Hill-Rom, where she was SVP and CFO until their acquisition in December 2021. Barbara graduated from Indiana University with a Bachelor of Science in Finance and later received an MBA from the same university.

    Mr. Keeling is currently a Senior Partner with McKinsey & Company, Chicago, and a leader in the company's global Life Sciences Practice, Operations Practice, and Quality, Compliance and Remediation Practice. David has worked for McKinsey and for clients across North America, Europe and Asia with areas of focus that include strategy, organization, mergers and acquisitions, operations, and supply chain management. He has spent more than 25 years serving the largest and most successful companies in biopharmaceuticals, including in areas such as oncology, cell and gene therapy, and contract manufacturing. David graduated from the University of Western Australia with a Bachelor of Engineering with first-class honors and later received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.

    In late 2023, NorthStar announced it would focus its business on delivering high-quality medical radioisotopes to the market and building out its radiopharmaceutical patient dose contract development and manufacturing organization (CDMO), both to accelerate growth and to make a more immediate measurable impact on the lives of patients with cancer and other serious illnesses.

    "2024 and the next few years will be critical for NorthStar," said Frank Scholz, Ph.D., NorthStar President and Chief Executive Officer. "We're on the cusp of a global paradigm shift in the development and commercialization of effective new radiodiagnostics and radiotherapies, and we believe NorthStar can be a key catalyst of this change. As we enter this next stage of our evolution and growth, the opportunities are enormous and having strong board members with a wealth of diverse, deep industry experience such as David and Barbara have will help us unlock the promise our business holds for our industry, doctors, and their patients."

    About NorthStar Medical Technologies, LLC (NorthStar)

    NorthStar Medical Technologies, based in Beloit, Wis., is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC. NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer. NorthStar's expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225). The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. For more information about NorthStar's comprehensive portfolio and patient-focused services, visit: www.northstarnm.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240227681309/en/

    Get the next $BMRN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BMRN
    $ENOV
    $OPCH
    $SYNH

    CompanyDatePrice TargetRatingAnalyst
    BioMarin Pharmaceutical Inc.
    $BMRN
    7/3/2025$97.00Overweight
    Morgan Stanley
    Option Care Health Inc.
    $OPCH
    4/30/2025$40.00Neutral → Buy
    UBS
    BioMarin Pharmaceutical Inc.
    $BMRN
    2/24/2025$98.00Perform → Outperform
    Oppenheimer
    Option Care Health Inc.
    $OPCH
    1/23/2025$26.00 → $35.00Hold → Buy
    Jefferies
    Option Care Health Inc.
    $OPCH
    1/13/2025$26.00 → $33.00Neutral → Buy
    BofA Securities
    Option Care Health Inc.
    $OPCH
    12/5/2024$26.00Neutral
    UBS
    BioMarin Pharmaceutical Inc.
    $BMRN
    11/15/2024$95.00Outperform
    Wolfe Research
    Option Care Health Inc.
    $OPCH
    11/4/2024$27.00Buy → Neutral
    Goldman
    More analyst ratings

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    SEC Filings

    See more
    • SEC Form 11-K filed by Enovis Corporation

      11-K - Enovis CORP (0001420800) (Filer)

      6/26/25 4:45:47 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Enovis Corporation

      SD - Enovis CORP (0001420800) (Filer)

      5/30/25 4:05:37 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by BioMarin Pharmaceutical Inc.

      8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)

      5/22/25 4:05:34 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Leadership Updates

    Live Leadership Updates

    See more
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lalor Angela S was granted 718 shares, increasing direct ownership by 4% to 20,553 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      7/1/25 9:00:05 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SVP, Chief Financial Officer Berry Phillip Benjamin (Ben) covered exercise/tax liability with 1,013 shares, decreasing direct ownership by 0.88% to 114,229 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      6/3/25 9:00:06 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Director Kelly Liam was granted 6,598 shares, increasing direct ownership by 51% to 19,604 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      5/23/25 9:00:06 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on BioMarin Pharmaceutical with a new price target

      Morgan Stanley resumed coverage of BioMarin Pharmaceutical with a rating of Overweight and set a new price target of $97.00

      7/3/25 7:59:58 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Option Care Health upgraded by UBS with a new price target

      UBS upgraded Option Care Health from Neutral to Buy and set a new price target of $40.00

      4/30/25 7:24:45 AM ET
      $OPCH
      Medical/Nursing Services
      Health Care
    • BioMarin Pharmaceutical upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded BioMarin Pharmaceutical from Perform to Outperform and set a new price target of $98.00

      2/24/25 8:15:22 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kraemer Harry M Jansen Jr bought $969,031 worth of shares (43,000 units at $22.54), increasing direct ownership by 15% to 326,334 units (SEC Form 4)

      4 - Option Care Health, Inc. (0001014739) (Issuer)

      11/13/24 5:27:03 PM ET
      $OPCH
      Medical/Nursing Services
      Health Care
    • Kraemer Harry M Jansen Jr bought $1,104,352 worth of shares (35,000 units at $31.55), increasing direct ownership by 15% to 269,528 units (SEC Form 4)

      4 - Option Care Health, Inc. (0001014739) (Issuer)

      2/28/24 4:41:59 PM ET
      $OPCH
      Medical/Nursing Services
      Health Care
    • Bierbower Elizabeth D bought $79,110 worth of shares (3,000 units at $26.37), increasing direct ownership by 29% to 13,515 units (SEC Form 4)

      4 - Option Care Health, Inc. (0001014739) (Issuer)

      11/1/23 5:09:51 PM ET
      $OPCH
      Medical/Nursing Services
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Option Care Health to Announce Second Quarter 2025 Financial Results and Host Conference Call

      BANNOCKBURN, Ill., June 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2025 on Wednesday, July 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI6761a41f2d314134ba5d574509278b8d. The call can also be accessed via a liv

      6/25/25 4:05:00 PM ET
      $OPCH
      Medical/Nursing Services
      Health Care
    • BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

      Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025. The Phase 3 GENEr8-1

      6/24/25 9:00:00 AM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Financials

    Live finance-specific insights

    See more
    • BioMarin Announces Completion of Acquisition of Inozyme

      SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (NASDAQ:INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious and progressive genetic condition that affects blood vessels, soft tissues and bones. On May 16, 2025, BioMarin and Inozyme announced tha

      7/1/25 8:45:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Option Care Health to Announce Second Quarter 2025 Financial Results and Host Conference Call

      BANNOCKBURN, Ill., June 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2025 on Wednesday, July 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI6761a41f2d314134ba5d574509278b8d. The call can also be accessed via a liv

      6/25/25 4:05:00 PM ET
      $OPCH
      Medical/Nursing Services
      Health Care
    • BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

      Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Inozyme Pharma, Inc. (NASDAQ:INZY) announced today that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share in an all-cash transa

      5/16/25 7:30:00 AM ET
      $BMRN
      $INZY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 29, 2023 - FDA Approves First Gene Therapy for Adults with Severe Hemophilia A

      For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca

      6/29/23 6:02:12 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMRN
    $ENOV
    $OPCH
    $SYNH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enovis Corporation

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      11/14/24 1:28:31 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Option Care Health Inc.

      SC 13G - Option Care Health, Inc. (0001014739) (Subject)

      11/8/24 10:46:38 AM ET
      $OPCH
      Medical/Nursing Services
      Health Care
    • SEC Form SC 13G filed by BioMarin Pharmaceutical Inc.

      SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)

      9/30/24 4:29:01 PM ET
      $BMRN
      Biotechnology: Pharmaceutical Preparations
      Health Care